A stressful life (or death): Combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability

Oncotarget

Volumn 2, Issue 4, 2011, Pages 277-280

  Workman, Paul ^a   Davies, Faith E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; PUROMYCIN; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN SYNTHESIS; QUALITY CONTROL; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; BIOLOGICAL MODEL; CELL DEATH; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MORTALITY; NEOPLASM; NOTE; PHYSIOLOGICAL STRESS; PHYSIOLOGY; UTILIZATION REVIEW;

ANTINEOPLASTIC AGENTS; CELL DEATH; COMBINATORIAL CHEMISTRY TECHNIQUES; HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; STRESS, PHYSIOLOGICAL; SUBSTRATE SPECIFICITY; UNFOLDED PROTEIN RESPONSE;

EID: 80053322010     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.266     Document Type: Article

References (17)

1. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011; 2: 209-21.
2. Davenport EL, Morgan GJ, Davies FE. Untangling the unfolded protein response. Cell Cycle. 2008; 7: 865-9.
3. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ, Davies FE. Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells. Blood. 2007; 110: 2641-2649.
4. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Advances in Cancer Research. 2006; 95: 323-348.
5. Powers MV, Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007;581:3758-69.
6. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ, Davies FE. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010 116(2):250-3.
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487-98.
8. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-6.
9. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC. Anti-myeloma activity of heat shock protein-90 inhibition. Blood. 2006;107:1092-100.
10. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I. A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clin Cancer Res. 2011;17:1561-70.
11. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol. 2007;25: 5410-7
12. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 2008; 14: 250-62.
13. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? Cell Cycle. 2010; 9: 1542-1550.
14. de Billy E, Powers MV, Smith JR, Workman P. Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell Cycle. 2009; 8: 3806-8.
15. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 2007; 130: 1005-18
16. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D, Smith EM, Powers MV, Sharp SY, Workman P, Morgan GJ, Davies FE. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia. 2010; 24: 1804-7.
17. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136: 823-37.